Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

The Nuclear Factor Erythroid 2 Related Factor 2 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Nuclear Factor Erythroid 2 Related Factor 2, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Nuclear Factor Erythroid 2 Related Factor 2 and features dormant and discontinued projects.

Key Therapy Areas in the Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market

In the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market the key therapy areas are Central Nervous System, Immunology, Gastrointestinal, Metabolic Disorders, Oncology, Cardiovascular, Genito Urinary System and Sex Hormones, Musculoskeletal Disorders, Respiratory, Genetic Disorders, Ophthalmology, Dermatology, Hematological Disorders, Infectious Disease, and Women’s Health.

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by Therapy Areas

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by Therapy Areas

For more therapy area insights, download a free report sample

Key MoA in the Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market

Nuclear Factor Erythroid 2 Related Factor 2 Activator has the highest number of pipeline products followed by Nuclear Factor Erythroid 2 Related Factor 2 Inhibitor.

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by MoA

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market are oral, topical, ophthalmic, intravenous, inhalational, intramuscular, and rectal. Oral has the highest number of pipeline products.

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market Analysis, by RoA

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market

The key molecule types in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market are Small Molecule, and Synthetic Peptide.

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by Molecule Type

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market

The major companies in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline drugs market are Reata Pharmaceuticals Inc, AKL Research and Development Ltd, Annji Pharmaceutical Co Ltd, Anteris Bio, Arbor Pharmaceuticals LLC, Bach Pharma Inc, Bayer AG, BioApex sro, Biogen Inc, Biotoxtech Co Ltd, C4X Discovery Holdings Plc, Cellix Bio Pvt Ltd, Complexa Inc, Cureveda LLC, and Daiichi Sankyo Co Ltd.

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by Major Companies

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline Drugs Market Overview

Key Therapy Areas Central Nervous System, Immunology, Gastrointestinal, Metabolic Disorders, Oncology, Cardiovascular, Genito Urinary System and Sex Hormones, Musculoskeletal Disorders, Respiratory, Genetic Disorders, Ophthalmology, Dermatology, Hematological Disorders, Infectious Disease, and Women’s Health
Key Mechanisms of action Nuclear Factor Erythroid 2 Related Factor 2 Activator, and Nuclear Factor Erythroid 2 Related Factor 2 Inhibitor
Key Routes of Administration Oral, Topical, Ophthalmic, Intravenous, Inhalational, Intramuscular, and Rectal
Key Molecule Types Small Molecule, and Synthetic Peptide
Major Companies Reata Pharmaceuticals Inc, AKL Research and Development Ltd, Annji Pharmaceutical Co Ltd, Anteris Bio, Arbor Pharmaceuticals LLC, Bach Pharma Inc, Bayer AG, BioApex sro, Biogen Inc, Biotoxtech Co Ltd, C4X Discovery Holdings Plc, Cellix Bio Pvt Ltd, Complexa Inc, Cureveda LLC, and Daiichi Sankyo Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nuclear Factor Erythroid 2 Related Factor 2
  • The pipeline guide reviews pipeline therapeutics for Nuclear Factor Erythroid 2 Related Factor 2 by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nuclear Factor Erythroid 2 Related Factor 2 therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nuclear Factor Erythroid 2 Related Factor 2 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Nuclear Factor Erythroid 2 Related Factor 2

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nuclear Factor Erythroid 2 Related Factor 2
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AKL Research and Development Ltd
Annji Pharmaceutical Co Ltd
Anteris Bio
Arbor Pharmaceuticals LLC
Bach Pharma Inc
Bayer AG
BioApex sro
Biogen Inc
Biotoxtech Co Ltd
C4X Discovery Holdings Plc
Cellix Bio Pvt Ltd
Complexa Inc
Cureveda LLC
Daiichi Sankyo Co Ltd
Erganeo
Evgen Pharma Plc
Haisco Pharmaceutical Group Co Ltd
Immungenetics AG
Ixchel Pharma LLC
Lignamed LLC
Mariposa Therapeutics Ltd
Mochida Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Rescue Therapeutics Inc
Scohia Pharma Inc
Sulfateq BV
Vitalis LLC
Vividion Therapeutics Inc
vTv Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) – Overview

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) – Companies Involved in Therapeutics Development

AKL Research and Development Ltd

Annji Pharmaceutical Co Ltd

Anteris Bio

Arbor Pharmaceuticals LLC

Bach Pharma Inc

Bayer AG

BioApex sro

Biogen Inc

Biotoxtech Co Ltd

C4X Discovery Holdings Plc

Cellix Bio Pvt Ltd

Complexa Inc

Cureveda LLC

Daiichi Sankyo Co Ltd

Erganeo

Evgen Pharma Plc

Haisco Pharmaceutical Group Co Ltd

Immungenetics AG

Ixchel Pharma LLC

Lignamed LLC

Mariposa Therapeutics Ltd

Mochida Pharmaceutical Co Ltd

Reata Pharmaceuticals Inc

Rescue Therapeutics Inc

Scohia Pharma Inc

Sulfateq BV

Vitalis LLC

Vividion Therapeutics Inc

vTv Therapeutics Inc

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) – Drug Profiles

(apocynin + paeonol) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(aspirin + dimethyl fumarate) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(aspirin + diroximel fumarate) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(aspirin + monomethyl fumarate) – Drug Profile

Product Description

Mechanism Of Action

History of Events

ALZ-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ALZ-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BA-1521 – Drug Profile

Product Description

Mechanism Of Action

bardoxolone methyl – Drug Profile

Product Description

Mechanism Of Action

History of Events

BTT-105 – Drug Profile

Product Description

Mechanism Of Action

History of Events

C4X-6746 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CLXNEU-06 – Drug Profile

Product Description

Mechanism Of Action

CXA-10 – Drug Profile

Product Description

Mechanism Of Action

History of Events

DH-404 – Drug Profile

Product Description

Mechanism Of Action

dimethyl fumarate – Drug Profile

Product Description

Mechanism Of Action

History of Events

dimethyl fumarate – Drug Profile

Product Description

Mechanism Of Action

History of Events

dimethyl fumarate DR – Drug Profile

Product Description

Mechanism Of Action

History of Events

diroximel fumarate DR – Drug Profile

Product Description

Mechanism Of Action

History of Events

HPP-3033 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HPP-971 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HSK-36212 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HYCO-13 – Drug Profile

Product Description

Mechanism Of Action

History of Events

IXC-103 – Drug Profile

Product Description

Mechanism Of Action

History of Events

LGM-2605 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MG-132 – Drug Profile

Product Description

Mechanism Of Action

MIND-4 – Drug Profile

Product Description

Mechanism Of Action

History of Events

monosodium luminol – Drug Profile

Product Description

Mechanism Of Action

History of Events

nifurtimox – Drug Profile

Product Description

Mechanism Of Action

History of Events

omaveloxolone – Drug Profile

Product Description

Mechanism Of Action

History of Events

RS-9 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RTI-79 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SCO-116 – Drug Profile

Product Description

Mechanism Of Action

SFX-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SFX-02 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate NFE2L2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate NFE2L2 for Neurodegenerative Diseases – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Activate NFE2L2 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Activate NRF2 for Chronic Kidney Disease and Inflammatory Bowel Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Nrf2 for Epidermolysis Bullosa – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Target GSK3B and Nrf2 for Alzheimer’s Disease – Drug Profile

Product Description

Mechanism Of Action

SUL-121 – Drug Profile

Product Description

Mechanism Of Action

TBE-31 – Drug Profile

Product Description

Mechanism Of Action

tepilamide fumarate – Drug Profile

Product Description

Mechanism Of Action

History of Events

TFM-735 – Drug Profile

Product Description

Mechanism Of Action

VCB-102 – Drug Profile

Product Description

Mechanism Of Action

VEDA-1209 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) – Dormant Products

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) – Discontinued Products

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) – Product Development Milestones

Featured News & Press Releases

Apr 04, 2022: Biogen announces new update on VUMERITY at AAN 2022

Mar 31, 2022: Reata Pharmaceuticals completes rolling submission of new drug application for Omaveloxolone for the treatment of patients with Friedreich’s Ataxia

Mar 17, 2022: Viatris defeats Biogen’s attempt to Revive Tecfidera patent

Mar 07, 2022: Evgen Pharma : Expansion of collaboration with the Manchester Breast Centre

Feb 25, 2022: Reata Pharmaceuticals receives complete response letter from the FDA for bardoxolone for the treatment of patients with chronic kidney disease caused by Alport syndrome

Feb 15, 2022: Haisco’s announcement on obtaining the “Notice of Acceptance” for clinical trial application of innovative drug HSK36212 capsules

Jan 31, 2022: Reata Pharmaceuticals initiates rolling submission of new drug application with U.S. FDA for Omaveloxolone for the treatment of patients with Friedreich’s ataxia

Jan 11, 2022: Evgen Pharma: Progress with UK and US regulators for 2022 clinical trials

Dec 14, 2021: Imara presents preclinical data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Dec 08, 2021: Reata Pharmaceuticals announces outcome of FDA advisory committee meeting of Bardoxolone for the treatment of patients with chronic kidney disease caused by alport syndrome

Dec 08, 2021: Reata Pharmaceuticals stock trading halted; FDA Advisory Committee to discuss bardoxolone for the treatment of patients with chronic kidney disease caused by Alport Syndrome

Dec 01, 2021: Viatris wins Federal circuit court appeal upholding district court decision invalidating Biogen’s Tecfidera Patent

Nov 18, 2021: Reata Pharmaceuticals receives Fast Track Designation from the FDA for Omaveloxolone for the treatment of Friedreich’s Ataxia

Nov 16, 2021: The European Commission grants marketing authorization for VUMERITY (diroximel fumarate) as oral treatment for relapsing-remitting multiple sclerosis

Nov 10, 2021: Evgen Pharma: Publication of data on SFX-01 in glioblastoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Indications, 2022 (Contd..3)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AKL Research and Development Ltd, 2022

Pipeline by Annji Pharmaceutical Co Ltd, 2022

Pipeline by Anteris Bio, 2022

Pipeline by Arbor Pharmaceuticals LLC, 2022

Pipeline by Bach Pharma Inc, 2022

Pipeline by Bayer AG, 2022

Pipeline by BioApex sro, 2022

Pipeline by Biogen Inc, 2022

Pipeline by Biotoxtech Co Ltd, 2022

Pipeline by C4X Discovery Holdings Plc, 2022

Pipeline by Cellix Bio Pvt Ltd, 2022

Pipeline by Complexa Inc, 2022

Pipeline by Cureveda LLC, 2022

Pipeline by Daiichi Sankyo Co Ltd, 2022

Pipeline by Erganeo, 2022

Pipeline by Evgen Pharma Plc, 2022

Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022

Pipeline by Immungenetics AG, 2022

Pipeline by Ixchel Pharma LLC, 2022

Pipeline by Lignamed LLC, 2022

Pipeline by Mariposa Therapeutics Ltd, 2022

Pipeline by Mochida Pharmaceutical Co Ltd, 2022

Pipeline by Reata Pharmaceuticals Inc, 2022

Pipeline by Rescue Therapeutics Inc, 2022

Pipeline by Scohia Pharma Inc, 2022

Pipeline by Sulfateq BV, 2022

Pipeline by Vitalis LLC, 2022

Pipeline by Vividion Therapeutics Inc, 2022

Pipeline by vTv Therapeutics Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Dormant Products, 2022 (Contd..3)

Dormant Products, 2022 (Contd..4)

Dormant Products, 2022 (Contd..5)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.